This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD (DINO)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: January 21, 2011
Last updated: October 27, 2016
Last verified: September 2016

Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4) for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment. With its mode of action Daxas can reduce exacerbations rates and improve lung function parameters which may result in a better health-related quality of life and an improved long-term management of COPD.

The aim of this non-interventional study is to evaluate data on quality of life in COPD patients in Germany in a real life medical setting. Evaluation is based on two COPD specific questionnaires to assess the patient`s health status over six months. During the study, socio-demographic data and cost-of-illness data will be recorded. Daxas (tablet) will be administered once daily. The study will provide further data on the safety and tolerability of Daxas.

Condition Intervention
Severe COPD Drug: Daxas

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Daxas in COPD Therapy

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Pre-/post comparison of the COPD status based on patients health status [ Time Frame: after 6 months ]
    Evaluation of treatment success by a COPD-specific patient questionnaire

Secondary Outcome Measures:
  • Effectiveness during treatment [ Time Frame: after 6 months ]
    Evaluation of treatment success by a health status patient questionnaire

  • Evaluation of tolerability [ Time Frame: after 6 months ]
    assessment of adverse drug reactions

  • Evaluation of cost-of-illness data [ Time Frame: before treatment ]
    number of consultations, sick leave, hospitalisation, number of and duration of rehab measures

  • Evaluation of sociodemographic data [ Time Frame: before treatment ]
    employment status, disease management programme

  • Evaluation of symptom reduction of sputum and cough [ Time Frame: after 6 months ]

Enrollment: 5472
Study Start Date: August 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
DINO Drug: Daxas
500 microgram, oral, once daily as add-on therapy to existing therapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients diagnosed with severe COPD.

Main Inclusion Criteria:

  • severe COPD

Main Exclusion Criteria:

  • Child pugh (classified B and C)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01285180

  Show 2412 Study Locations
Sponsors and Collaborators
Study Director: AstraZeneca AstraZeneca AstraZeneca
  More Information

Responsible Party: AstraZeneca Identifier: NCT01285180     History of Changes
Other Study ID Numbers: RO-2455-402-DE
U1111-1136-8860 ( Registry Identifier: WHO )
Study First Received: January 21, 2011
Last Updated: October 27, 2016

Keywords provided by AstraZeneca:
Quality of life
sociodemographic data
cost-of-illness data
Daxas processed this record on September 21, 2017